Search results
Results From The WOW.Com Content Network
The American Cancer Society recommends that men have a chance to make an informed decision with their health care provider about whether to be screened for prostate cancer. The decision should be made after getting information about the possible benefits, risks, and uncertainties of prostate cancer screening .
The goal of screening for prostate cancer is to identify high-risk, localized prostate cancer that can be successfully treated, thereby preventing the morbidity and mortality associated with advanced or metastatic prostate cancer.
The goal of screening for prostate cancer is to find cancers that may be at high risk for spreading if not treated, and to find them early before they spread. If you are thinking about being screened, learn about the possible benefits and harms of screening, diagnosis, and treatment, and talk to your doctor about your personal risk factors.
The guideline provides detailed recommendations for clinicians concerning the core factors related to prostate cancer screening and treatment that should be shared with men to enable them to make a truly informed decision regarding whether to be screened.
In 2018, the US Preventive Services Task Force (USPSTF) made the following recommendations about prostate cancer screening: Men who are 55 to 69 years old should make individual decisions about being screened for prostate cancer with a prostate specific antigen (PSA) test.
See Current Final Recommendation Statement for Prostate Cancer: Screening (2018) The Task Force follows a multistep process when developing each of its recommendations. Use the graphic below to see where this recommendation is in the development process. Learn about our full development process. Opportunity for Comment.
Early detection and screening both imply detection of disease at an early, pre-symptomatic stage when a man would have no reason to seek medical care –an intervention referred to as secondary prevention.
PSA screening for prostate cancer should involve consideration of benefits and risks. Screening is associated with a small reduction in prostate cancer deaths; risks include overdiagnosis...
Screening for prostate cancer is done with a simple blood test called a prostate-specific antigen (PSA) test. This test measures the level of a protein made by cells in the prostate gland in your blood. PSA levels rise if there’s a problem with your prostate. It’s normal to have a low level of PSA. What is my risk for prostate cancer?
Conclusions and RecommendationFor men aged 55 to 69 years, the decision to undergo periodic PSA-based screening for prostate cancer should be an individual one and should include discussion of the potential benefits and harms of screening with their clinician.